FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of virology2002; 76(3); 1510-1515; doi: 10.1128/jvi.76.3.1510-1515.2002

Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors.

Abstract: This report compares gene transfer efficiencies as well as durations and levels of gene expression for human immunodeficiency virus (HIV) and equine infectious anemia virus (EIAV) lentiviral vectors in a variety of human cell types in vitro. EIAV and HIV vectors transduced equivalent numbers of proliferating and G1/S- and G2/M-arrested cells, and both had very low efficiencies of transduction into G0-arrested cells. Analysis of the levels of both the enhanced green fluorescent protein (EGFP) and mRNA demonstrated that the HIV-transduced cells expressed greater levels of EGFP protein and RNA than the EIAV-transduced cells. Measurements of vector-derived EGFP RNA half-lives were fourfold higher with the HIV vector than with the EIAV vector. Long-term culture of EIAV-transduced human cells showed a significant decrease in the number of cells expressing the transgene; however, no corresponding loss was found in EIAV-transduced equine cells. In contrast, only a moderate decrease in the number of transgene-expressing cells was seen with the HIV vectors. Taken together, these results demonstrate that the EIAV vectors transduced human cells with efficiencies similar to those of the HIV vectors. However, our data indicate that transgene expression from EIAV vectors is limited by the instability of vector-derived RNA transcripts and silencing of the EIAV vectors over time.
Get Full Text
Publication Date: 2002-01-05 PubMed ID: 11773424PubMed Central: PMC135783DOI: 10.1128/jvi.76.3.1510-1515.2002Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research explores the efficiency of gene transfer and expression when using the human immunodeficiency virus (HIV) and equine infectious anemia virus (EIAV) lentiviral vectors on various human cell types. The study revealed that while both vetor types showed comparable gene transfer efficiencies, the HIV vectors demonstrated higher levels of gene expression and long-term gene stability.

Research Method and Results

  • The researchers tested the gene transfer efficiencies of HIV and EIAV vectors across various human cell types in a controlled laboratory setting.
  • Both the HIV and EIAV vectors were able to transduce an equivalent number of proliferating cells and also G1/S- and G2/M-arrested cells (cells in different phase of cell cycle) implying that cell cycle stage does not impact the transduction efficiency of each vector.
  • However, both vectors demonstrated low efficiency when transducing G0-arrested cells (non-dividing or quiescent stage cells).
  • Next, the researchers looked at the levels of the enhanced green fluorescent protein (EGFP) and mRNA. They found that cells which had been transduced by HIV vectors expressed more EGFP protein and RNA than cells having been transduced with EIAV.
  • The study revealed that the half-lives of vector-derived EGFP RNA were four times higher with the HIV vector compared to the EIAV vector.

Long-Term Culture and Transgene Expression

  • The scientists observed that the long-term culture of EIAV-transduced human cells led to a significant decrease in the number of cells expressing the transgene, implying loss of gene expression over time.
  • No such loss in gene expression was observed in EIAV-transduced equine cells, demonstrating a potential species-specific limitation.
  • On the other hand, there was only a moderate decrease in the number of transgene-expressing cells long-term when the HIV vectors were used.

Conclusion

  • Although both EIAV and HIV vectors demonstrated similar efficiencies in gene transfer, differences were observed in the level of transgene expression and its stability over time.
  • The results suggest EIAV vectors have limited effectiveness due to the instability of vector-derived RNA transcripts and silencing of the vector over time.
  • Therefore, HIV vectors might be a superior choice for gene therapy applications requiring sustained gene expression in human cells.

Cite This Article

APA
O'Rourke JP, Newbound GC, Kohn DB, Olsen JC, Bunnell BA. (2002). Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors. J Virol, 76(3), 1510-1515. https://doi.org/10.1128/jvi.76.3.1510-1515.2002

Publication

Journal of virology
ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 76
Issue: 3
Pages: 1510-1515

Researcher Affiliations

O'Rourke, J P
  • Children's Research Institute, Children's Hospital, Columbus, Ohio 43205, USA.
Newbound, G C
    Kohn, D B
      Olsen, J C
        Bunnell, B A

          MeSH Terms

          • Animals
          • Cell Line
          • Cell Line, Transformed
          • Gene Expression
          • Gene Transfer Techniques
          • Genes, Reporter
          • Genetic Vectors / genetics
          • Green Fluorescent Proteins
          • HIV-1 / genetics
          • Horses
          • Humans
          • Infectious Anemia Virus, Equine / genetics
          • Lentivirus / genetics
          • Luminescent Proteins / genetics
          • Luminescent Proteins / metabolism
          • RNA Stability
          • RNA, Messenger
          • Time Factors
          • Transduction, Genetic
          • Tumor Cells, Cultured

          Grant Funding

          • F32 HL010430 / NHLBI NIH HHS
          • R01 AI047693 / NIAID NIH HHS
          • AI47693 / NIAID NIH HHS
          • HL10430 / NHLBI NIH HHS

          References

          This article includes 17 references
          1. Arya SK, Zamani M, Kundra P. Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging.. Hum Gene Ther 1998 Jun 10;9(9):1371-80.
            pubmed: 9650621doi: 10.1089/hum.1998.9.9-1371google scholar: lookup
          2. Berkowitz R, Ilves H, Lin WY, Eckert K, Coward A, Tamaki S, Veres G, Plavec I. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus.. J Virol 2001 Apr;75(7):3371-82.
            pmc: PMC114130pubmed: 11238863doi: 10.1128/JVI.75.7.3371-3382.2001google scholar: lookup
          3. Berkowitz RD, Ilves H, Plavec I, Veres G. Gene transfer systems derived from Visna virus: analysis of virus production and infectivity.. Virology 2001 Jan 5;279(1):116-29.
            pubmed: 11145895doi: 10.1006/viro.2000.0659google scholar: lookup
          4. Bestor TH. Gene silencing. Methylation meets acetylation.. Nature 1998 May 28;393(6683):311-2.
            pubmed: 9620794doi: 10.1038/30613google scholar: lookup
          5. Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors.. Mol Ther 2000 Jan;1(1):31-8.
            pubmed: 10933909doi: 10.1006/mthe.1999.0007google scholar: lookup
          6. D'Costa J, Brown HM, Kundra P, Davis-Warren A, Arya SK. Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation.. J Gen Virol 2001 Feb;82(Pt 2):425-434.
            pubmed: 11161282doi: 10.1099/0022-1317-82-2-425google scholar: lookup
          7. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences.. Nat Genet 2000 Jun;25(2):217-22.
            pubmed: 10835641doi: 10.1038/76095google scholar: lookup
          8. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications.. Virology 1999 Aug 15;261(1):120-32.
            pubmed: 10441560doi: 10.1006/viro.1999.9850google scholar: lookup
          9. McInerney JM, Nawrocki JR, Lowrey CH. Long-term silencing of retroviral vectors is resistant to reversal by trichostatin A and 5-azacytidine.. Gene Ther 2000 Apr;7(8):653-63.
            pubmed: 10800088doi: 10.1038/sj.gt.3301155google scholar: lookup
          10. Metharom P, Takyar S, Xia HH, Ellem KA, Macmillan J, Shepherd RW, Wilcox GE, Wei MQ. Novel bovine lentiviral vectors based on Jembrana disease virus.. J Gene Med 2000 May-Jun;2(3):176-85.
            pubmed: 10894263doi: 10.1002/(SICI)1521-2254(200005/06)2:3<176::AID-JGM106>3.0.CO;2-Qgoogle scholar: lookup
          11. Mitrophanous K, Yoon S, Rohll J, Patil D, Wilkes F, Kim V, Kingsman S, Kingsman A, Mazarakis N. Stable gene transfer to the nervous system using a non-primate lentiviral vector.. Gene Ther 1999 Nov;6(11):1808-18.
            pubmed: 10602376doi: 10.1038/sj.gt.3301023google scholar: lookup
          12. Mselli-Lakhal L, Favier C, Da Silva Teixeira MF, Chettab K, Legras C, Ronfort C, Verdier G, Mornex JF, Chebloune Y. Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors.. Arch Virol 1998;143(4):681-95.
            pubmed: 9638141doi: 10.1007/s007050050323google scholar: lookup
          13. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.. Science 1996 Apr 12;272(5259):263-7.
            pubmed: 8602510doi: 10.1126/science.272.5259.263google scholar: lookup
          14. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus.. Gene Ther 1998 Nov;5(11):1481-7.
            pubmed: 9930301doi: 10.1038/sj.gt.3300768google scholar: lookup
          15. Tarantal AF, O'Rourke JP, Case SS, Newbound GC, Li J, Lee CI, Baskin CR, Kohn DB, Bunnell BA. Rhesus monkey model for fetal gene transfer: studies with retroviral- based vector systems.. Mol Ther 2001 Feb;3(2):128-38.
            pubmed: 11237669doi: 10.1006/mthe.2000.0255google scholar: lookup
          16. Yamada K, Olsen JC, Patel M, Rao KW, Walsh CE. Functional correction of fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector.. Mol Ther 2001 Apr;3(4):485-90.
            pubmed: 11319908doi: 10.1006/mthe.2001.0287google scholar: lookup
          17. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors.. J Virol 1999 Apr;73(4):2886-92.
            pmc: PMC104046pubmed: 10074136doi: 10.1128/JVI.73.4.2886-2892.1999google scholar: lookup

          Citations

          This article has been cited 20 times.
          1. Bonaventure B, Rebendenne A, Chaves Valadão AL, Arnaud-Arnould M, Gracias S, Garcia de Gracia F, McKellar J, Labaronne E, Tauziet M, Vivet-Boudou V, Bernard E, Briant L, Gros N, Djilli W, Courgnaud V, Parrinello H, Rialle S, Blaise M, Lacroix L, Lavigne M, Paillart JC, Ricci EP, Schulz R, Jouvenet N, Moncorgé O, Goujon C. The DEAD box RNA helicase DDX42 is an intrinsic inhibitor of positive-strand RNA viruses. EMBO Rep 2022 Nov 7;23(11):e54061.
            doi: 10.15252/embr.202154061pubmed: 36161446google scholar: lookup
          2. Munis AM. Gene Therapy Applications of Non-Human Lentiviral Vectors. Viruses 2020 Sep 29;12(10).
            doi: 10.3390/v12101106pubmed: 33003635google scholar: lookup
          3. Li W, Singh PK, Sowd GA, Bedwell GJ, Jang S, Achuthan V, Oleru AV, Wong D, Fadel HJ, Lee K, KewalRamani VN, Poeschla EM, Herschhorn A, Engelman AN. CPSF6-Dependent Targeting of Speckle-Associated Domains Distinguishes Primate from Nonprimate Lentiviral Integration. mBio 2020 Sep 29;11(5).
            doi: 10.1128/mBio.02254-20pubmed: 32994325google scholar: lookup
          4. Morrison JH, Miller C, Bankers L, Crameri G, Wang LF, Poeschla EM. A Potent Postentry Restriction to Primate Lentiviruses in a Yinpterochiropteran Bat. mBio 2020 Sep 15;11(5).
            doi: 10.1128/mBio.01854-20pubmed: 32934084google scholar: lookup
          5. Doyle T, Moncorgé O, Bonaventure B, Pollpeter D, Lussignol M, Tauziet M, Apolonia L, Catanese MT, Goujon C, Malim MH. The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry. Nat Microbiol 2018 Dec;3(12):1369-1376.
            doi: 10.1038/s41564-018-0273-9pubmed: 30478388google scholar: lookup
          6. Wang F, Chen W, Liu P, Zhou J, Liu B, Ye W, Wang W, Shen X. Lentivirus-mediated RNAi knockdown of LMP2A inhibits the growth of the Epstein-Barr-associated gastric carcinoma cell line GT38 in vitro. Exp Ther Med 2017 Jan;13(1):187-193.
            doi: 10.3892/etm.2016.3954pubmed: 28123488google scholar: lookup
          7. Lopes VS, Williams DS. Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7A. Cold Spring Harb Perspect Med 2015 Jan 20;5(6).
            doi: 10.1101/cshperspect.a017319pubmed: 25605753google scholar: lookup
          8. Tang Y, Garson K, Li L, Vanderhyden BC. Optimization of lentiviral vector production using polyethylenimine-mediated transfection. Oncol Lett 2015 Jan;9(1):55-62.
            doi: 10.3892/ol.2014.2684pubmed: 25435933google scholar: lookup
          9. Goujon C, Moncorgé O, Bauby H, Doyle T, Barclay WS, Malim MH. Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. J Virol 2014 Aug;88(16):9017-26.
            doi: 10.1128/JVI.01269-14pubmed: 24899177google scholar: lookup
          10. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward CC, Schaller T, Hué S, Barclay WS, Schulz R, Malim MH. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 2013 Oct 24;502(7472):559-62.
            doi: 10.1038/nature12542pubmed: 24048477google scholar: lookup
          11. Luo F, Sun X, Wang Y, Wang Q, Wu Y, Pan Q, Fang C, Zhang XL. Ficolin-2 defends against virulent Mycobacteria tuberculosis infection in vivo, and its insufficiency is associated with infection in humans. PLoS One 2013;8(9):e73859.
            doi: 10.1371/journal.pone.0073859pubmed: 24040095google scholar: lookup
          12. Matreyek KA, Engelman A. The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol 2011 Aug;85(15):7818-27.
            doi: 10.1128/JVI.00325-11pubmed: 21593146google scholar: lookup
          13. Goujon C, Malim MH. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol 2010 Sep;84(18):9254-66.
            doi: 10.1128/JVI.00854-10pubmed: 20610724google scholar: lookup
          14. Krishnan L, Matreyek KA, Oztop I, Lee K, Tipper CH, Li X, Dar MJ, Kewalramani VN, Engelman A. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase. J Virol 2010 Jan;84(1):397-406.
            doi: 10.1128/JVI.01899-09pubmed: 19846519google scholar: lookup
          15. Howarth JL, Lee YB, Uney JB. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol 2010 Feb;26(1):1-20.
            doi: 10.1007/s10565-009-9139-5pubmed: 19830583google scholar: lookup
          16. Zeng L, Yang S, Wu C, Ye L, Lu Y. Effective transduction of primary mouse blood- and bone marrow-derived monocytes/macrophages by HIV-based defective lentiviral vectors. J Virol Methods 2006 Jun;134(1-2):66-73.
            doi: 10.1016/j.jviromet.2005.12.006pubmed: 16430973google scholar: lookup
          17. Hanawa H, Persons DA, Nienhuis AW. Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors. J Virol 2005 Jul;79(13):8410-21.
            doi: 10.1128/JVI.79.13.8410-8421.2005pubmed: 15956585google scholar: lookup
          18. Logan AC, Haas DL, Kafri T, Kohn DB. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol 2004 Aug;78(16):8421-36.
            doi: 10.1128/JVI.78.16.8421-8436.2004pubmed: 15280451google scholar: lookup
          19. Giannoukakis N, Trucco M. Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitus. Rev Endocr Metab Disord 2003 Dec;4(4):369-80.
            doi: 10.1023/a:1027306213563pubmed: 14618022google scholar: lookup
          20. Hurez V, Hautton RD, Oliver J, Matthews RJ, Weaver CK. Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction. Immunol Res 2002;26(1-3):131-41.
            doi: 10.1385/ir:26:1-3:131pubmed: 12403352google scholar: lookup
          Subscribe to our newsletter
          Join 99,658 horse owners like you who receive our email updates on horse health and nutrition.